- Medical - Diagnostics & Research
- Healthcare
-
7.81
EPS
-
30.41
P/E
-
43.3B
MARKET CAP
-
0.00%
DIV YIELD
Company Overview
4820 EMPEROR BLVD.,DURHAM NC 27703,919-998-2000
CEO
Mr. Ari Bousbib
Employess
88000
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Website
https://www.iqvia.com
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Next Earnings Date
Nov. 6, 2024
Ex Dividends date
--
Dividend Date
--
YTD Performance
3.07%
Fiscal Year End
12-31
IPO Date
2013-05-09
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 11.40% | 7.58% | 9.72% | 4.13% |
| EPS | 14.98% | 42.22% | 71.70% | 26.98% |
| Equity | 27.28% | -1.86% | 0.61% | 6.02% |
| Cash | 5.87% | 9.08% | -8.80% | 13.16% |
| Return On Capital (ROIC) | 9.76% | 5.99% | 7.98% | 9.74% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 825 | 152 | 91 | 149 | 100 |
| Long Term Debt | 13,000 | 12,900 | 12,300 | 12,800 | 11,900 |
| LT Finance Leases | 451 | 264 | 313 | 371 | 396 |
| Shares Outstanding | 184 | 188 | 191 | 191 | 195 |
| Market Cap | 42,500 | 38,400 | 54,000 | 34,300 | 30,100 |
Price
News
Understanding IQVIA (IQV) Reliance on International Revenue
2 monthsExamine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
zacks.com
IQV vs. WAT: Which Stock Should Value Investors Buy Now?
2 monthsInvestors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Waters (WAT). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
2 monthsThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
These Analysts Boost Their Forecasts On IQVIA After Better-Than-Expected Earnings
2 monthsIQVIA Holdings Inc IQV posted better-than-expected second-quarter earnings on Monday.
benzinga.com
Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics
2 monthsAlthough the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
IQVIA Stock Pops After It Beats Q2 Earnings Estimates
2 monthsIQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.
investopedia.com
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2
2 monthsIQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.
zacks.com
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings
2 monthsIQVIA Holdings Inc IQV reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.
benzinga.com
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
2 monthsIQVIA Holdings (IQV) came out with quarterly earnings of $2.64 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to earnings of $2.43 per share a year ago.
zacks.com
IQVIA raises annual profit forecast on improving demand for analytics services
2 monthsContract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.
reuters.com
IQVIA Reports Second-Quarter 2024 Results
2 monthsRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2024. Second-Quarter 2024 Operating Results Revenue for the second quarter of $3,814 million increased 2.3 percent on a reported basis and 3.5 percent at constant currency, compared to the second quarter of 2023.
businesswire.com
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
2 monthsIQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.
zacks.com